Loading
A phase 3 trial of FAP-2286, Enzalutamide, Abiraterone acetate in prostate cancer, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) is a phase 3 interventional study registered as NCT06520345 by Telix Pharmaceuticals (Innovations) Pty Limited, with 520 participants planned, started 2024-07-26 and due to reach its primary completion in 2027-12. Interventions recorded: 177Lu-TLX591, Enzalutamide, Abiraterone, Docetaxel. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Abiraterone acetate, Enzalutamide, Docetaxel, Metastatic castration-resistant prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares FAP-2286 (177Lu / 68Ga), Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Docetaxel, Metastatic castration-resistant prostate cancer.
Shares Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Docetaxel, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Docetaxel, Metastatic castration-resistant prostate cancer, Prostate cancer.